Ceramedix, Inc.

About Ceramedix, Inc.

Ceramedix is a preclinical, privately held company focused on pioneering novel therapies for diseases driven by microvascular injury. Their mission is to address unmet medical needs and transform patient lives through innovative treatments.

Products & Services

Anti-Ceramide Antibodies:A first-in-class therapy targeting microvascular injury, with a lead program focused on early treatment of Diabetic Retinopathy and Diabetic Macular Edema. The treatment enables early pharmacologic intervention, addresses the root cause of disease, and is administered subcutaneously, eliminating the need for intravitreal injections.

Specialties

Microvascular Injury Therapies Anti-Ceramide Antibodies Diabetic Retinopathy and Diabetic Macular Edema Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 3007043 MR: - FA: $3,007,043 FAN: 3007043	D: 2023-08-24 FD: 2023-08-24	2 investors

Grant Latest

2023-08-24

$3.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Samia Mohammed

Research Scientist I

O

Olivia Beane, PhD

Project Manager

L

Linda Law, MD, MBA

Development, Medical, and Commercial Strategy Consultant

J

James M. Joly

Preclinical Safety and Toxicology Consultant

K

Kira Manusis

Competitive Strategy Advisor

T

Thomas J. MacVittie

Radiation Research Consultant

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

Ceramedix, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised